Drug Type Small molecule drug |
Synonyms ARG, GBS-01, NSC-206269 |
Target |
Action agonists, inhibitors, stimulants |
Mechanism ADIPOR1 agonists(Adiponectin receptor protein 1 agonists), PDHK1 inhibitors(pyruvate dehydrogenase kinase 1 inhibitors), PP2A stimulants(Protein phosphatase 2A stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H24O6 |
InChIKeyNQWVSMVXKMHKTF-JKSUJKDBSA-N |
CAS Registry7770-78-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Arctigenin |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 2 | Japan | - | - |
Pancreatic Cancer | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Osteosarcoma | Preclinical | China | 01 May 2025 | |
Osteosarcoma | Preclinical | China | 01 May 2025 | |
Diabetic Nephropathies | Preclinical | China | 15 Nov 2016 | |
Diabetic Nephropathies | Preclinical | - | 15 Nov 2016 | |
Inflammation | Preclinical | United States | 01 Feb 2016 | |
Peanut Hypersensitivity | Preclinical | United States | 01 Feb 2016 |
Not Applicable | Prader-Willi Syndrome GH peak | IGF1 levels | 28 | hfdjwpyitm(xcaognmrlv) = igohoaupzm fupnjmcxwu (yiumraqjhy ) | - | 18 Sep 2014 | ||
Phase 1 | 15 | ljwimfytxx(azisrrajxq) = lacwjebkwa cxvtakqvof (vhjfctybmk ) View more | - | 20 May 2013 | |||
GBS-01 7.5g | ljwimfytxx(azisrrajxq) = wmlftstexl cxvtakqvof (vhjfctybmk ) View more |